Bone Biologics Corp Warrants (BBLGW)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Bone Biologics Corp Warrants (BBLGW) is down 6.5% since the beginning of the year. At $15 per share, BBLGW is trading 59.7% below its 52-week high of $36.

Bone Biologics Corp Warrants (BBLGW) has returned -6.45% so far this year and -3.33% over the past 12 months.

Based on dividend-adjusted daily data since Oct 13, 2021, BBLGW's average daily return is +1.07%, while the average monthly return is +21.04%. At this rate, an investment would double in approximately 0.3 years.

Historically, 39% of months were positive and 61% were negative. The best month was Dec 2023 with a return of +330.8%, while the worst month was Oct 2023 at -82.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, BBLGW closed higher 20% of trading days. The best single day was Oct 21, 2024 with a return of +172.7%, while the worst single day was Oct 18, 2024 at -81.8%.

Bone Biologics Corp Warrants has an annualized alpha of 1351.09%, beta of 0.02, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since October 13, 2021.

• This stock captured 372.96% of S&P 500 Index gains and 244.06% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• Beta of 0.02 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BBLGW ranks 50 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Bone Biologics Corp Warrants. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bone Biologics Corp Warrants was 98.80%, occurring on Jun 9, 2023. Recovery took 234 trading sessions.

The current Bone Biologics Corp Warrants drawdown is 84.74%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Bone Biologics Corp Warrants over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Bone Biologics Corp Warrants is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.